Asparagine endopeptidase (AEP)

Molecular Classification

Enzyme, Cysteine protease, Endopeptidase, Lysosomal enzyme, Member of C13 peptidase family (Clan CD), EC 3.4.22.34

Other Names

legumain, δ-secretase, asparaginyl endopeptidase, LGMN gene product, PRSC1 gene product, mammalian legumain, proteinase B, hemoglobinase, citvac, vicilin peptidohydrolase, bean endopeptidase (context-dependent, especially in plants)

Disease Roles

CancerNeurodegenerative disease (Alzheimer's disease, Parkinson’s disease, brain ischemia/stroke)Inflammation

Asparagine endopeptidase Overview

Asparagine endopeptidase (AEP) is a lysosomal cysteine protease primarily responsible for cleaving peptide bonds at the C-terminus of asparagine residues. Encoded by the LGMN gene in humans, AEP (also called legumain or δ-secretase) is involved in protein and peptide degradation predominantly in late endosomes and lysosomes[1][3][5]. It plays crucial roles in antigen processing, regulation of cell death, and maturation of immune receptors such as TLRs[1][4]. AEP is tightly regulated by pH, remaining inactive at neutral pH and becoming activated under acidic conditions typical of lysosomes[1][2][5]. Dysregulation of AEP activity has been implicated in various pathologies, notably neurodegenerative diseases like Alzheimer’s and Parkinson’s (through cleavage of tau, amyloid precursor protein, and SET protein), certain cancers, stroke, and chronic inflammation[2][3][4]. While there are no approved drugs directly targeting AEP, selective inhibitors are being explored in preclinical models for their potential therapeutic benefits[3][4][5].

Mechanism of Action

Competitive or irreversible inhibition of the AEP catalytic cysteine site, preventing substrate cleavage at asparagine residues

Biological Functions

Proteolytic processing (cleavage after asparagine residues)

Protein and peptide degradation in endolysosomal compartments

Maturation of toll-like receptors (e.g., TLR3/7/9)

Regulation of cell death and apoptosis (especially in neurons)

Modulation of immune response (antigen presentation, lysosomal processing)

Formation of cyclotides and peptide ligation (primarily in plants, tool for biotechnology)

Disease Associations

Cancer

Neurodegenerative disease (Alzheimer's disease, Parkinson’s disease, brain ischemia/stroke)

Inflammation

Atherosclerosis

Stroke

Safety Considerations

Risk of interfering with physiological protein processing in lysosomes and antigen presentation
Possible effects on immune function or tissue homeostasis due to disruption of normal substrate turnover
Broad inhibition may cause off-target toxicity (as AEP is widely expressed in many tissues)
Compensatory mechanisms by upregulation of other proteases

Interacting Drugs

Experimental AEP inhibitors (e.g., Cbz-L-Ala-L-Ala-AzaAsn-chloromethylketone, aza-peptidyl inhibitors)

E64 (broad cysteine protease inhibitor, sometimes reported as AEP inhibitor in research)

Natural endogenous inhibitors (e.g., cystatin C as a regulatory protein)

No clinically approved drugs currently directly target AEP.

Associated Biomarkers

Biomarker
Elevated AEP protein levels or activity (biomarker for Alzheimer's, Parkinson’s, certain cancers, and stroke)
Cleaved products (e.g., tau, amyloid precursor protein, SET fragments in the CNS) can indicate pathological AEP activation